Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernews.google.com
selinexor multiple myeloma - Google News
Get the latest updates from selinexor multiple myeloma - Google News directly as they happen.
Follow now < 10 followers
Latest posts
Last updated over 3 years ago
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer - Stockhouse
over 3 years ago
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in...
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer - 69News WFMZ-TV
over 3 years ago
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in...
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer - Marketscreener.com
over 3 years ago
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in...
Selecting Appropriate Treatment for Patients With Heavily Pretreated Multiple Myeloma - OncLive
over 3 years ago
Selecting Appropriate Treatment for Patients With Heavily Pretreated Multiple Myeloma OncLive
Karyopharm Names New Head of Investor Relations - GuruFocus.com
over 3 years ago
Karyopharm Names New Head of Investor Relations GuruFocus.com
Karyopharm Names New Head of Investor Relations - Marketscreener.com
over 3 years ago
Karyopharm Names New Head of Investor Relations Marketscreener.com
Karyopharm Names New Head of Investor Relations | News | wfmz.com - 69News WFMZ-TV
over 3 years ago
Karyopharm Names New Head of Investor Relations | News | wfmz.com 69News...
Selinexor, Bortezomib and Dexamethasone for Myeloma | OTT - Dove Medical Press
over 3 years ago
Selinexor, Bortezomib and Dexamethasone for Myeloma | OTT Dove Medical Press
Huge ADC deals, but cancer index down 35% on company disappointments - BioWorld Online
over 3 years ago
Huge ADC deals, but cancer index down 35% on company disappointments BioWorld...
Approved Treatment for Relapsed and Refractory Multiple Myeloma - eTurboNews | TravelWireNews
over 3 years ago
Approved Treatment for Relapsed and Refractory Multiple Myeloma eTurboNews | TravelWireNews
Karyopharm Therapeutics : Corporate Presentation March 2022 - Marketscreener.com
over 3 years ago
Karyopharm Therapeutics : Corporate Presentation March 2022 Marketscreener.com
Looking Forward into 2022 in Multiple Myeloma With Robert Orlowski, MD, PHD, MD Anderson Cancer Center - Myeloma Crowd News
over 3 years ago
Looking Forward into 2022 in Multiple Myeloma With Robert Orlowski, MD, PHD...